Behind Every Policy is a Family

Get Involved

TIMELINE OF THERAPY DEVELOPMENT FOR HEMOPHILIA

  • BEFORE 1938

    AVERAGE LIFE EXPECTANCY: 11 YEARS OLD

    TREATMENTS AVAILABLE: NONE

  • BEFORE 1968

    AVERAGE LIFE EXPECTANCY: 20 YEARS OLD

    TREATMENTS AVAILABLE: PLASMA OR WHOLE BLOOD TRANSFUSIONS

  • 1968

    AVERAGE LIFE EXPECTANCY: LESS THAN 40 YEARS OLD

    TREATMENTS AVAILABLE: CRYOPRECIPITATE

  • 1983

    AVERAGE LIFE EXPECTANCY: 40 YEARS OLD

    TREATMENTS AVAILABLE: FREEZE DRIED CLOTTING FACTORS **IMPACT OF AIDS/HIV ON BLOOD SUPPLY

  • 1988

    AVERAGE LIFE EXPECTANCY: **IMPACT OF AIDS/HIV ON BLOOD SUPPLY

    TREATMENTS AVAILABLE: FREEZE DRIED CLOTTING FACTORS

  • 1999

    AVERAGE LIFE EXPECTANCY: NORMAL LIFESPAN

    TREATMENTS AVAILABLE: GENETICALLY ENGINEERED CLOTTING FACTORS (RECOMBINATE)

  • EARLY 2000S

    AVERAGE LIFE EXPECTANCY: NORMAL LIFESPAN

    TREATMENTS AVAILABLE: NEW NOVEL THERAPY AVAILABLE (EXTENDED HALFLIFE)

  • 2010S

    AVERAGE LIFE EXPECTANCY: NORMAL LIFESPAN

    TREATMENTS AVAILABLE: SUBCUTANEOUS TREATMENTS

    GENE THERAPY CLINICAL TRIALS

  • TODAY

    FDA APPROVES GENE THERAPY FOR HEMOPHILIA A & B

    ADDITIONAL CLINICAL TRIALS CONTINUE FOR BOTH HEMOPHILIA A & B